Clinical Trial Update: Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the combination of RMC-4630 and LY3214996 in metastatic KRAS-mutant cancers has been terminated. The study encompassed pancreatic cance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Kras-mutant Cancers
• Non-small Cell Lung Cancer
• Pancreatic Cancer

Drugs mentioned

• LY3214996
• RMC-4630

Snippet

Sponsor: The Netherlands Cancer Institute | Conditions: Pancreatic Cancer, Colorectal Cancer | Phase 1 | Status: TERMINATED